A New Dawn in Drug Discovery
In the ever-evolving tapestry of pharmaceutical innovation, Bristol Myers Squibb (BMS) has embarked on a transformative journey. By acquiring Nvidia's DGX SuperPOD, based on the pioneering Vera Rubin architecture, BMS is set to redefine the landscape of drug discovery. This acquisition marks a significant milestone, as BMS becomes the first life sciences entity to deploy such advanced technology.
The Power of Nvidia's SuperPOD
The DGX SuperPOD, a formidable cluster of eight DGX Vera Rubin NVL72 systems, is equipped with Nvidia's latest CPUs and GPUs. This technological marvel is designed to exponentially enhance BMS's computational capabilities, which already include an older SuperPOD system. The integration of this new infrastructure is not merely a technological upgrade; it is a strategic leap towards harnessing the full potential of artificial intelligence in drug development.
Unleashing the Potential of AI
Artificial intelligence, the modern-day alchemist, is already woven into the fabric of BMS's operations. From the design of small and large molecule programs to target identification and lead optimization, AI is transforming the pharmaceutical landscape. With the new SuperPOD, BMS aims to reduce manual labor by weeks, accelerating drug production for clinical trials by 20-30%, with aspirations of reaching 50%.
Bridging Science and Innovation
The acquisition of Nvidia's system is more than a technological enhancement; it is a bridge connecting scientists across the globe. Managed by Nvidia Mission Control, this unified infrastructure will facilitate seamless data and model sharing among BMS's global research sites. As Erin Davis, Vice President at BMS, aptly puts it, "The compute infrastructure is what connects all of our scientists together and ensures that our learnings are institutionalised."